Profund Advisors LLC Sells 5,706 Shares of Alexion Pharmaceuticals, Inc. (ALXN)
Profund Advisors LLC lessened its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 100,538 shares of the biopharmaceutical company’s stock after selling 5,706 shares during the quarter. Alexion Pharmaceuticals accounts for approximately 0.6% of Profund Advisors LLC’s portfolio, making the stock its 26th biggest position. Profund Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $12,232,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Guardian Life Insurance Co. of America boosted its stake in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at about $111,000. Fiduciary Trust Co. purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $111,000. Huntington National Bank boosted its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares during the period. Finally, Penserra Capital Management LLC boosted its stake in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 94.26% of the company’s stock.
Several brokerages have recently issued reports on ALXN. UBS AG reiterated a “buy” rating and issued a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 31st. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Finally, Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, June 8th. Five research analysts have rated the stock with a hold rating, twenty have given a buy rating and three have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $157.13.
In other news, EVP Julie O’neill sold 11,160 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock worth $2,416,869 over the last quarter. Insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up 1.44% on Friday, hitting $146.69. The stock had a trading volume of 3,713,613 shares. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a market cap of $32.74 billion, a price-to-earnings ratio of 63.61 and a beta of 1.40. The company’s 50 day moving average price is $138.83 and its 200-day moving average price is $124.75.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s quarterly revenue was up 21.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.13 EPS. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.62 EPS for the current year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.